Inside China's response to COVID.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Sheet, Surveillance, Strategy, Salvage and Shield in global biodefense system to protect the public health and tackle the incoming pandemics.The Science of the total environment · 2022
   Review
2. Coronavirus disease 2019 vaccines: perspectives and update.Medical journal, Armed Forces India · 2021
   Article
3. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.Lancet (London, England) · 2021
   Review
4. What Explains Natives and Sojourners Preventive Health Behavior in a Pandemic: Role of Media and Scientific Self-Efficacy.Frontiers in psychology · 2021
   Article

Corrections and comments

• Comment on
  A new coronavirus associated with human respiratory disease in China.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as